NCT07521852 2026-04-22
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
Clinical Trials
11 trialsNCT07490262 2026-04-16
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3 Recruiting
NCT07455617 2026-04-06
Study of ABO2102 in KRAS-Mutated Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Phase 1 Recruiting
NCT05427487 2026-03-25
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd
Phase 1 Recruiting
NCT06497985 2026-03-19
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT06530251 2026-03-04
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Akeso
Phase 1/2 Recruiting
NCT05504278 2025-01-27
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Recruiting
NCT06584032 2025-01-07
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
Phase 3 Recruiting
NCT06558227 2024-12-16
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Recruiting
NCT05804526 2024-04-30
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT05890742 2024-03-15
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Recruiting